免疫系统
肿瘤微环境
免疫疗法
肝细胞癌
癌症研究
间质细胞
免疫学
生物
医学
作者
Bernhard Scheiner,David J. Pinato
标识
DOI:10.1053/j.gastro.2023.01.025
摘要
Xue R, Zhang Q, Cao Q, et al. Liver tumor immune microenvironment subtypes and neutrophil heterogeneity. Nature 2022;612:141–147. Therapeutic modulation of the tumor microenvironment (TME) by anticancer immunotherapy is transforming treatment of hepatocellular and cholangiocellular carcinoma and intense research efforts are devoted to the identification of the elusive 20%–30% of patients in whom treatment success cannot be predicted a priori by any available biomarker. Xue et al performed comprehensive single-cell RNA-sequencing characterization of 189 samples derived from 124 patients undergoing primary curative resection for hepatocellular carcinoma (n = 79) and intrahepatic cholangiocellular carcinoma (n = 25). Based on immune cell composition and gene expression profiles, patients were stratified into five distinctive subtypes, reflecting TME polarization toward mutually exclusive functional characteristics: spontaneous immune activation, myeloid or stromal-induced immune suppression, and immune exclusion, as well as an immune-resident phenotype. Although consolidated evidence suggests that spontaneous immune activation is linked with enhanced responsiveness to immunotherapy, this study describes the multifaceted cellular and molecular determinants that hinder spontaneous tumor immune recognition. For instance, tumor-promoting macrophages secreting IL-1β are hallmarks of myeloid-derived suppression, whereas overexpression of collagen type 1 alpha 1 and matrix metalloproteinase-11 is typical of a stromal dominance. Such a detailed insight into the cross-talk between the malignancy and surrounding TME is crucial to guide biomarker identification, as well as patient selection for targeted interventions, reinforced by the association between immune suppression and a worse prognosis. Among the most relevant players of cancer immune suppression, tumor-associated neutrophils emerged as polyfunctional actors in follow-on experiments. In vitro-induced tumor-associated neutrophils expressing checkpoint molecules hindered the cytotoxic activity of T cells, an effect that could be reversed by the addition of anti–programmed cell death ligand 1 targeted treatment or therapeutic neutrophil depletion slowing tumor progression in a mouse model. In summary, the present study significantly extends our knowledge by introducing 5 different subsets of tumors specifically characterized not only on a cellular, but also on a molecular level. The chosen approach highlights the substantial heterogeneity existing in liver tumors and provides grounds for the expanding theme of deep tissue phenotyping as a pathway leading to personalized treatment approaches. A lack of correlation with immunotherapy outcomes and limited clinical applicability of complex profiling based on single-cell technology stand as important hurdles to clinical implementation in routine practice. Nevertheless, the work by Xue et al provides important experimental evidence on the composition and function of the TME and its cross-talk with the tumor, as well as the importance of tumor-associated neutrophils. Further studies will need to evaluate how to boost immunotherapy efficacy and the potential role of targeted tumor-promoting neutrophil depletion and systemic treatment personalization according to different TME phenotypes.
科研通智能强力驱动
Strongly Powered by AbleSci AI